News articles about Incyte Corporation (NASDAQ:INCY) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Incyte Corporation earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.8370833638355 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the headlines that may have impacted Accern Sentiment’s analysis:

Shares of Incyte Corporation (INCY) opened at 114.70 on Friday. The stock has a 50 day moving average of $121.38 and a 200 day moving average of $127.20. The stock’s market cap is $23.59 billion. Incyte Corporation has a one year low of $83.01 and a one year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.01). Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The firm had revenue of $326.40 million during the quarter, compared to analyst estimates of $318.45 million. During the same period last year, the business earned $0.18 EPS. The firm’s revenue was up 32.5% on a year-over-year basis. Equities analysts expect that Incyte Corporation will post ($0.83) EPS for the current fiscal year.

Several equities research analysts recently commented on the stock. BidaskClub lowered shares of Incyte Corporation from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Jefferies Group LLC reiterated a “buy” rating on shares of Incyte Corporation in a research note on Friday. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Incyte Corporation in a research note on Friday. They set a “buy” rating and a $160.00 price target on the stock. Cowen and Company reiterated an “outperform” rating and set a $130.00 price target on shares of Incyte Corporation in a research note on Monday, July 3rd. Finally, Credit Suisse Group reiterated a “buy” rating on shares of Incyte Corporation in a research note on Saturday, June 10th. Seven equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $144.84.

COPYRIGHT VIOLATION NOTICE: This news story was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at

In related news, President Herve Hoppenot sold 70,502 shares of the stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $119.45, for a total value of $8,421,463.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bros. Advisors Lp Baker acquired 100,000 shares of the company’s stock in a transaction that occurred on Friday, September 8th. The stock was purchased at an average cost of $132.00 per share, for a total transaction of $13,200,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 109,452 shares of company stock worth $13,707,134. Corporate insiders own 17.70% of the company’s stock.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.